The Effect of Virtual Reality Glasses Application on Pain, Anxiety, and Patient Satisfaction

August 18, 2022 updated by: Rumeysa Lale TORAMAN, Ataturk University

The Effect of Virtual Reality Glasses Application on Pain, Anxiety, and Patient Satisfaction During a Transrectal Prostate Biopsy: A Randomized Controlled Trial

The study was conducted in a randomized controlled manner to determine the effect of applying virtual reality glasses during transrectal prostate biopsy on pain, anxiety and patient satisfaction.The study was completed with a total of 70 patients, 35 in the intervention group and 35 in the control group, for whom it was decided to perform sample transrectal prostate biopsy for the first time.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Although prostate cancer is the most common type of cancer in men, according to 2018 data published by the International Agency for Research on Cancer, it is the second most common after lung cancer worldwide.The prevalence of prostate cancer is increasing rapidly worldwide. However, when prostate cancer is diagnosed early, the survival rate increases with the effect of the treatment methods applied. Digital rectal examination (DRE), prostate specific antigen (PSA) level, and transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) methods are used for diagnosis. Transrectal prostate biopsy process; It is one of the most frequently performed urological procedures for definitive diagnosis in patients with a PSA value above the normal limit and abnormal DRE findings. Transrectal prostate biopsy is a golden diagnostic tool in prostate cancer because it is typically well tolerated, treatable, and has a low risk of major complications. However, in addition to the advantages of this procedure, it also has disadvantages such as causing pain and discomfort in patients.Prostate biopsy procedure affects patients not only physiologically but also psychologically. Interventional procedures cause patients to experience the highest level of anxiety. With the development of technology, developments in health care have brought the concept of patient satisfaction to the fore. Applications made in line with patient expectations in order to increase the quality of care make a significant contribution to the perception of nursing care. One of these applications, virtual reality glasses, make patients feel like they are in a different world; increases patient satisfaction. Nurses, who are members of the profession who plan and manage care, because they spend longer time with the patient; They play an active role in defining pain and anxiety by using pharmacological and non-pharmacological methods. When examining the literature, there was no study examining the effect of virtual reality application on the pain level of patients during the transrectal prostate biopsy procedure, but no study examining the effect on the level of anxiety and patient satisfaction. In this study; It is aimed to increase patient satisfaction by reducing the pain and anxiety of the patients with virtual reality applied during the transrectal prostate biopsy procedure. It is thought that the results of this study can make an important contribution to both the literature and practice.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
70

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Erzurum
      • Palandöken, Erzurum, Turkey, 25000
        • Rumeysa Lale TORAMAN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Those between the ages of 18-65,
  • Those who volunteer and accept to participate in the research,
  • Transrectal prostate biopsy procedure performed for the first time,
  • No communication problem,
  • Cognitive level scales are suitable for application,
  • Patients without vision or hearing problems were included in the study.

Exclusion Criteria:

  • Leaving work voluntarily,
  • Patients whose cognitive level scales were not suitable for application were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Virtual Reality Glasses
The intervention introductory information formula was face-to-face by researchers from the State-Trait Anxiety Inventory (STAI-I, STAI-II), the Scale of Patient Perception of Hospital Experience with Nursing Care (PPHEN) and Visual Analog Scale for Pain (VAS) Before starting the research, a preliminary application plan is determined with 10 virtual virtual applications. It is not included in the applications made in the pre-application. Before watching the video, patients are informed about how to train, how to do it, and detailed information about the video. When the patient is removed from the service and in the left lateral position, 2 minutes before the assistant physician, the virtual is about to take place. The video was watched after about 10-15 minutes until the process was finished. After the procedure, STAI-I, STAI-II, PPHEN and VAS were reapplied by the researchers.
Device: Virtual Reality Glasses
The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
State-Trait Anxiety İnventory (STAI-I, STAI-II)
Time Frame: up to 24 hours
It is a test developed by Spielberger et al. that measures state and trait anxiety levels. Its validity and reliability in Turkey was done by Öner and Le Compte. The scale consists of two parts, the 'state anxiety scale', which is created with the aim of determining the instantaneous feelings, and the 20-item 'trait anxiety scale', which was created to determine the feelings in general. It is a four degree scale ranging from 'Nothing' to 'All'. Scores range from 20 (low anxiety) to 80 (high anxiety).
up to 24 hours
The Scale of Patient Perception of Hospital Experience with Nursing Care (PPHEN)
Time Frame: up to 24 hours
The patient's perception of nursing care scale was developed by Dozier et al. in the USA, and its Turkish validity and reliability were determined by Çoban and Kaşıkçı.Likert-type scale has 15 statements about the quality of nursing care. A minimum of 15 and a maximum of 75 points can be obtained from the scale. The cut-off point of the scale is 45. Scores above the cut-off point indicate a positive attitude. The increase in the total score obtained from the scale indicates that the patient is satisfied with the nursing care.
up to 24 hours
Visual Analog Scale for Pain (VAS)
Time Frame: up to 24 hours
VAS is a scale developed by Price et al34 (1983) and measures the severity of pain in the patient. VAS is a 10 cm long vertical or horizontal scale with two different names (0=no pain, 10=most severe pain). An increase in the score obtained from the scale in the evaluation indicates an increase in pain.
up to 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ataturk University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: RUMEYSA LALE TORAMAN, Ataturk University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 25, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 20, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 27, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 17, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 18, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 19, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 19, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 18, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Rumeysa

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings